News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Julia Laurin

Advertisement

Articles by Julia Laurin

Julia Laurin

Lessons Learned Working with Millions of Patients on Specialty Medications

ByJulia Laurin
June 28th 2021

Additional assistance necessary for patients prescribed specialty therapies.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    WHO Finalizes United States’ Withdrawal from Organization: Report

    2

    JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry

    3

    Novavax Enters $530 Million License Agreement with Pfizer for Vaccine Development

    4

    Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics

    5

    What is Daiichi Sankyo’s Post JP Morgan Strategy?

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us